Relay Therapeutics, Inc. filings document the regulatory record of a clinical-stage precision-medicine company developing small molecule programs for cancer and genetic disease. Form 8-K reports include operating and financial results, Regulation FD clinical updates for zovegalisib, FDA Breakthrough Therapy designation disclosure, material agreements, capital-structure matters, and governance changes.
Proxy materials describe board composition, committee structure, executive compensation, equity awards, shareholder voting matters, and related governance policies. Other filings address amendments to bylaws, including exclusive-forum provisions, and securities disclosures tied to RLAY common stock and its development-stage pipeline.
Relay Therapeutics, Inc. (RLAY) President and CEO Sanjiv Patel sold 48,202 shares at a weighted-average sale price of $16.13 per share on November 19, 2026; trades ranged from $15.89 to $16.72. The sale was under a Rule 10b5-1 trading plan adopted October 30, 2025. Patel directly held 423,099 shares after the sale. The Patel Family Irrevocable Trust of 2019 held 199,548 shares, and The SSP Irrevocable Trust of 2020 held 687,355. Both trusts benefit family members and have an independent trustee; Patel disclaims beneficial ownership.
Relay Therapeutics, Inc. (RLAY) President, R&D Donald A. Bergstrom sold 10,269 common shares on November 18, 2026, at a weighted average sale price of $16.51 per share; individual trades ranged from $16.30 to $16.99. The sale was made under a Rule 10b5-1 trading plan adopted October 30, 2025. After the sale, he reported 386,609 direct shares, including 5,013 shares underlying restricted stock units.
Relay Therapeutics, Inc. (RLAY) Chief Financial Officer Thomas Catinazzo sold 32,717 shares of common stock at a weighted average price of $16.51 on November 18, 2026. The sale was made under a Rule 10b5-1 trading plan adopted October 30, 2025. His reported position after the sale was 70,948 shares, including 3,269 shares underlying restricted stock units.
Relay Therapeutics, Inc. (RLAY) reports that Officer Donald Bergstrom gave notice of a proposed sale of 10,269 common shares, with an aggregate market value of $169,130.43 and an approximate sale date of November 18, 2026. The notice lists October 30, 2025 as the adoption date for a Rule 10b5-1 plan. Bergstrom's sales during the prior three months included 2,252 shares on October 28, 2026, for gross proceeds of $41,932.24, and 8,530 shares on September 8, 2026, for gross proceeds of $161,775.72; the latter is listed under 10b5-1 sales. The shares proposed for sale were acquired upon vesting of restricted stock units during June 26, 2022 through July 27, 2023.
Relay Therapeutics, Inc. (RLAY) was the issuer for which SB Investment Advisers (UK) Limited, SoftBank Vision Fund (AIV M2) L.P., and SVF Pauling (Cayman) Limited reported shared beneficial ownership of 21,904,963 shares, or 9.9% of the common stock, as of September 30, 2026. The ownership figure was based on 220,959,470 common shares outstanding as of October 30, 2026.
T. Rowe Price Investment Management, Inc. reported beneficial ownership of 17,868,157 Relay Therapeutics, Inc. (RLAY) common shares, or 8.2% of the class. It reported sole voting power over 17,031,683 shares and sole dispositive power over 17,868,157 shares, with no shared voting or dispositive power. The company expressly denied being the beneficial owner and said the disclosure should not be construed as an admission of beneficial ownership.
Relay Therapeutics, Inc. reported a third-quarter 2026 net loss of $81.745 million, compared with $74.149 million a year earlier; net loss per share was ($0.37) versus ($0.43). Research and development expense was $77.138 million, up from $68.262 million. For the first nine months, net loss was $238.743 million versus $221.589 million, while license and other revenue was $3.350 million versus $8.355 million.
Cash, cash equivalents and investments totaled $848.6 million as of September 30, 2026. Relay expects those resources to fund operating expenses and capital expenditures into 2029, based on assumptions that may prove wrong. Net cash used in operations for the nine months was $169.155 million, compared with $190.590 million. In May 2026, Relay completed a public offering of 26,354,167 common shares at $12.00 per share, receiving $296.8 million net.
The FDA granted full approval in September 2026 for LYRFIGTU (lirafugratinib), as a treatment option for cholangiocarcinoma with FGFR2 fusion or other rearrangement. Elevar was granted exclusive global development and commercialization rights; Relay is eligible for up to $485.0 million in regulatory and commercial milestone payments plus tiered royalties. Relay initiated a Phase 3 registrational study of zovegalisib plus fulvestrant in advanced breast cancer.
Relay Therapeutics, Inc. reported a third-quarter 2026 net loss of $81.7 million ($0.37 per share), compared with $74.1 million ($0.43 per share) a year earlier. Cash, cash equivalents and investments were $848.6 million as of September 30, 2026; Relay expects these resources to fund operating expenses and capital expenditure requirements into 2029.
Enrollment in the Phase 3 ReDiscover-2 trial of zovegalisib plus fulvestrant is estimated to finish in mid-2027 based on the current enrollment trajectory, approximately one year faster than recent benchmarks. Updated ReInspire vascular-anomaly data are scheduled for an oral presentation at ASH on December 14, 2026; Relay plans a conference call afterward with a regulatory update. For first-line breast cancer, Relay expects a regulatory update on the planned Phase 3 design by year-end 2026 and plans trial initiation in early 2027.
Relay disclosed a mutant-selective TIE2 inhibitor in late-stage preclinical development. The FDA granted full approval to LYRFIGTU (lirafugratinib) for cholangiocarcinoma with FGFR2 fusion or other rearrangement, the first approved medicine from Relay’s Dynamo platform. Relay licensed worldwide development and commercialization rights to Elevar in December 2024.
Relay Therapeutics, Inc. Chief Corporate Development Officer Peter Rahmer reported selling 753 shares of common stock on October 28, 2026, at $18.62 per share. The sale covered income tax withholding obligations after 3,051 restricted stock units vested on October 27, 2026. Rahmer reported holding 222,904 shares directly afterward, including shares underlying RSUs. No Rule 10b5-1 plan is reported.
Relay Therapeutics, Inc. President, R&D Donald A. Bergstrom sold 2,252 shares of common stock on October 28, 2026, at $18.62 per share to cover income tax withholding after 5,012 restricted stock units vested on October 27, 2026. No Rule 10b5-1 plan is reported. He held 396,878 shares after the sale, including 5,013 shares underlying RSUs.